Skip to content

Poseida Therapeutics (PSTX) Stock Rockets 79% On Roche Deal

Poseida Therapeutics (NASDAQ:PSTX) stock is soaring on Wednesday after the clinical-stage biotechnology company announced a deal with Roche (OTCMKTS:RHHBY).

The agreement with Roche will have it working with Poseida Therapeutics to develop “allogeneic CAR-T therapies directed to hematologic malignancies.” This will grant Roche exclusive rights or options to develop and commercialize a collection of CAR-T programs from Poseida Therapeutics’ portfolio.

More about PSTX Stock here.

This post originally appeared at InvestorPlace.